Atropos Health, a healthcare technology company specializing in personalized real-world evidence, has secured $33 million in a Series B funding round. The investment, which includes contributions from industry giants McKesson, Merck, and Cencora Ventures, highlights the growing interest in Atropos’ mission to provide high-quality evidence for patient care decisions.
The Silicon Valley-based startup plans to utilize the new funding to expand its operations and focus on key initiatives such as entering the life sciences sector, forming channel partnerships in value-based care and oncology, and expanding its network of data partners.
CEO and co-founder Brigham Hyde, PhD, expressed the company’s commitment to democratizing personalized evidence for healthcare globally. Atropos’ core technology, Geneva OS, leverages AI and automation to generate clinical-grade evidence from real-world data, enabling healthcare stakeholders to access reliable evidence tailored to specific patient populations.
Hyde emphasized the importance of closing the “evidence gap” in healthcare, where only 14% of daily medical decisions are supported by high-quality evidence. By providing clinicians with personalized evidence based on similar patient profiles, Atropos aims to improve patient outcomes and reduce costs.
Furthermore, Atropos’ technology is not limited to clinical decision-making but also extends to pharmaceutical research and development. The company collaborates with pharmaceutical giants like Janssen to accelerate drug development by informing clinical trial design and patient recruitment.
With a strong financial backing and strategic partnerships, Atropos is poised to revolutionize healthcare delivery by providing personalized, automated clinical evidence. Hyde envisions a future where all patients and providers have access to quality, personalized evidence to make informed decisions, ultimately improving healthcare outcomes globally.